New COVID-19 vaccine study for those with prior mRNA vaccines
Part of Infections, Lungs & breathing clinical trials.
This study tests a new type of COVID-19 vaccine that is designed to train your immune system to make stronger, longer-lasting protection. You may be able to join if you are 40–64, have already had at least two doses of a mRNA COVID-19 vaccine (Pfizer or Moderna) more than 4 months ago, and are generally healthy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 64 years old.
- You have had at least two doses of the Pfizer or Moderna COVID-19 vaccine, with your last dose more than 4 months ago.
- You test negative for COVID-19 at the screening visit.
- You have no recent (within 120 days) COVID-19 infection or vaccination.
- You are not taking medications that weaken your immune system (such as steroids, chemotherapy, or other immunosuppressants) and have no active autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of COVID-19 booster vaccine that targets a protein to help your immune system. It's for people who already had a primary vaccine series and at least one mRNA booster, with the last booster at least 6 months ago.
This trial tests a new COVID-19 vaccine called VYD2311, alone or with another COVID-19 vaccine, in healthy adults. The goal is to see if it is safe and helps your body fight the virus.
This Phase 2 study tests a booster vaccine made from a COVID-19 protein (XBB + prototype) to help your immune system respond better. You may be able to join if you’re an adult who is due for a booster and meets health and safety screening checks.
This Phase 3 trial tests a booster vaccine made from a three-part COVID-19 protein (aimed at XBB, BA.5, and Delta) to see how well it works and is tolerated. It may help adults who are due for a COVID-19 booster, including people with certain health conditions, depending on screening results.
This trial tests a new nasal spray booster for COVID-19 in adults 18–64 who have already had a primary vaccine series and at least one booster. The goal is to see if it is safe and triggers a good immune response.
This trial tests a nasal spray booster for people who have already had 2-3 doses of COVID-19 inactivated vaccine. It studies if the spray is safe and boosts your immune system. You can join if you are healthy, have not had COVID-19 in the last 3 months, and had your last vaccine dose more than 6 months ago.
Hear when a new COVID-19 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.